Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale
Abstract Background Rituximab has become a standard treatment for non‐Hodgkin lymphoma. Clinical studies have demonstrated the efficacy of rituximab in combination with standard chemotherapies in the treatment of follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL) patients. This non‐i...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Jezik: | English |
| Izdano: |
Wiley
2023-02-01
|
| Serija: | Cancer Medicine |
| Teme: | |
| Online dostop: | https://doi.org/10.1002/cam4.5160 |